Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CEST

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
07/20 EDWARDS LIFESCIENCES' : Trademark Application for "EDWARDS SAPIEN" Filed
07/20 EDWARDS LIFESCIENCES : Trademark Application for "THRUPORT" Filed by Edwards Lif..
07/16 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Ju..
07/12 EDWARDS LIFESCIENCES : To Host Earnings Conference Call On July 26, 2017
07/06 EDWARDS LIFESCIENCES : An Application for the Trademark "QUALCRIMP" Has Been Fil..
07/06 EDWARDS LIFESCIENCES : Studies from University of Ulm Provide New Data on Aortic..
07/06 Global Tissue Heart Valve Materials Sales Market 2017 - St. Jude Medical, Edw..
07/05 EDWARDS LIFESCIENCES : ' INSPIRIS RESILIA Valve Receives FDA Approval
06/29 EDWARDS LIFESCIENCES : New Bioprosthetics Findings from Guangdong General Hospit..
06/28 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Ju..
More news
News from SeekingAlpha
07/20 Individual Stocks Are Still Lucrative - Cramer's Mad Money (7/19/17)
07/17 Wedgewood Partners Q2'17 Client Letter - The Fab Five
07/05 Edwards Lifesciences lands FDA approval for heart valve
07/05 DAILY INSIDER RATINGS ROUND UP 7/3/1 : Mcc, cnbka, opk, cara, kfs, mmac
06/16 Neovasc loses court case in Germany over Tiara patent; shares down 16%
Financials ($)
Sales 2017 3 352 M
EBIT 2017 1 006 M
Net income 2017 777 M
Finance 2017 471 M
Yield 2017 -
P/E ratio 2017 32,91
P/E ratio 2018 29,84
EV / Sales 2017 7,24x
EV / Sales 2018 6,52x
Capitalization 24 759 M
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Technical analysis trends EDWARDS LIFESCIENCES CORP
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 124 $
Spread / Average Target 5,0%
EPS Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John T. Cardis Independent Director
William J. Link Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES CORP25.94%24 759
THERMO FISHER SCIENTIFIC INC.29.11%71 272
DANAHER6.69%57 694
BOSTON SCIENTIFIC CORPORATION27.69%37 823
INTUITIVE SURGICAL46.25%34 169
ROYAL PHILIPS6.86%33 996